Dyadic Netherlands to develop enzymes for E.U.-funded research consortium

Monday, July 2, 2012 11:49 AM

Dyadic International, a global biotechnology company focused on enzymes and other proteins, announced that its R&D center in the Netherlands, a member of the multidisciplinary research consortium Bio-Mimetic Project, has been awarded a $4.4 million grant from the European Community's Seventh Framework Programme (FP7) of the European Community for Research, Technological Development and Demonstration Activities.

The European consortium is commencing a three year research project titled, “New Bio-Inspired Processes and Products from Renewable Feedstock” which will employ environmentally-friendly technologies to convert the renewable agricultural waste stream, lignin, into high value sustainable commercial products such as adhesives, detergents and cosmetics.

“We are very pleased to have the opportunity to work with such fine organizations on a highly innovative project where we can demonstrate the efficacy and productivity of our C1 technology to use green chemistry to find commercial applications for lignin,” Wim van der Wilden, general manager of Dyadic Netherlands. “If successful, this project will be a promising step forward in using this renewable waste stream to replace traditional toxic, expensive and high energy consuming processes.”

As part of the Bio-Mimetic Project, Dyadic Netherlands will receive approximately $500,000 to develop enzymes using Dyadic’s patented and proprietary C1 platform technology to degrade and modify lignin so that it can be used to create these high value commercial products.

Procter & Gamble Technical Centers will serve as the coordinator of the Bio-Mimetic Project Consortium which includes: Fraunhofer Institute (Germany); The University of Rome Tor Vergata (Italy); MAVI Sud (Italy); Gulgi B.V. (The Netherlands); Compagnie Industrielle de la Matiere Vegetale (France); Procter & Gamble Eurocor (Belgium); CiaoTech (Italy); and the University of Manchester (U.K.).

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 15

Cancer Treatment Centers of America chooses WCG as its exclusive IRB, sheds five local hospital IRBs

Five southern research groups form public-private network to help save time, money for clients with early-stage biologics

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

November

Private equity driving dynamic CRO growth
Enables CROs to pursue long-term strategies, while giving the space credibility

Baby boomers poised to reshape clinical trials industry
Millions of tech-savvy consumers already track their health, expect new treatments as they age

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs